Highlights of This Issue 4275

SPECIAL FEATURES

CCR Translations

4277 Immunotherapy of Cancer Visualized by Live Microscopy: Seeing Is Believing
Alvaro Teijeira, Iñaki Etxeberria, Mariano Ponz-Sarvise, and Ignacio Melero
See related article, p. 4417

4280 Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer
Adam Sharp, Jonathan Welti, Julian Blagg, and Johann S. de Bono
See related article, p. 4466

CCR New Strategies

4283 New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints
Victoria E. Wang, Jennifer R. Grandis, and Andrew H. Ko

Statistics in CCR

4291 Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials
Ying Yuan, Kenneth R. Hess, Susan G. Hilsenbeck, and Mark R. Gilbert

Molecular Pathways

4302 Molecular Pathways: The Balance between Cancer and the Immune System Challenges the Therapeutic Specificity of Targeting Nuclear Factor-κB Signaling for Cancer Treatment
Kristen P. Zeligs, Monica K. Neuman, and Christina M. Annunziata

Review

4309 Mutational Landscape and Sensitivity to Immune Checkpoint Blockers
Roman M. Chabanon, Marion Pedrero, Céline Lefebvre, Aurélien Marabelle, Jean-Charles Soria, and Sophie Postel-Vinay

PERSPECTIVE

4322 Cancer Prevention and Interception: A New Era for Chemopreventive Approaches
Adriana Albini, Andrea DeCensi, Franco Cavalli, and Alberto Costa

CANCER THERAPY: CLINICAL

4328 Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies

4341 A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement
Leo Rasche, Emmanuelle Menoret, Valentina Dubljevic, Eline Menu, Karin Vanderkerken, Constantin Lapa, Torsten Steinbrunn, Manik Chatterjee, Stefan Knop, Johannes Düll, Deanne L. Greenwood, Frank Henzel, Andreas Rosenwald, Hermann Einsele, and Stephanie Brändlein

PERSONALIZED MEDICINE AND IMAGING

4350 A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
Florence Magrangeas, Rowan Kuiper, Hervé Avet-Loiseau, Wilfried Gouraud, Catherine Guérin-Charbonnel, Iasovic Ferrer, Alexandre Aussem, Haytham Elghazel, Jérôme Suhard, Henri Der Sakissian, Michael Attal, Nikhil C. Munshi, Pieter Sonneveld, Charles Dumontet, Philippe Moreau, Mark van Duin, Loïc Campion, and Stéphane Minvielle

4356 Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma
Manuela Krumbholz, Julia Hellberg, Benedikt Steif, Tobias Bäuerle, Clarissa Gillmann, Torsten Fritscher, Abbas Agaimy, Benjamin Frey, Ioerg Juergert, Eva Wedelmann, Wolfgang Hartmann, Heribert Juergens, Uta Dirksen, and Markus Metzler
A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia
Nisar A. Amin, Erlene Seymour, Kamlai Saiya-Cork, Brian Parkin, Kerby Shedden, and Sami N. Malek

Correction: Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane–Anthracycline Containing Chemotherapy—DAFNE (GBG-70)

ABOUT THE COVER
CEA TCB (magenta), a novel T-cell bispecific antibody, specifically binds LS174T tumor cells (red) subcutaneously grafted with huPMBCs (green T cells) into the skin of mice. Tumor-cell targeting by CEA TCB is demonstrated by intravital, 2-photon microscopic imaging, 24 hours after intravenous injection of fluorescently (A647) labeled CEA TCB. For details, see the article by Lehmann and colleagues on page 4417 of this issue.